Advertisement

Infection

, Volume 46, Issue 2, pp 271–274 | Cite as

Neisseria cinerea bacteremia in a patient receiving eculizumab: a case report

  • Thomas L. Walsh
  • Holly R. Bean
  • Robert B. Kaplan
Case Report
  • 205 Downloads

Abstract

Neisseria cinerea is a commensal species capable of colonizing the upper respiratory tract of humans. Bacteremia associated with this organism is very uncommon, with only seven previous cases described. We report a case of Neisseria cinerea bacteremia in a patient maintained on indefinite eculizumab therapy. It is the eighth reported case of Neisseria cinerea bacteremia and represents the first case in a patient receiving eculizumab.

Keywords

Neisseria cinerea Nonpathogenic Neisseria Bacteremia Eculizumab 

Notes

Compliance with ethical standards

Conflict of interest

On behalf of all authors, the corresponding author states that there is no conflict of interest.

References

  1. 1.
    Knapp JS, Hook EW. Prevalence and persistence of Neisseria cinerea and other Neisseria spp. in adults. J Clin Microbiol. 1988;26:896–900.PubMedPubMedCentralGoogle Scholar
  2. 2.
    Knapp JS, Totten PA, Mulks MH, Minshew BH. Characterization of Neisseria cinerea, a nonpathogenic species isolated on Martin-Lewis medium selective for pathogenic Neisseria spp. J Clin Microbiol. 1984;19:63–7.PubMedPubMedCentralGoogle Scholar
  3. 3.
    Clausen CR, Knapp JS, Totten PA. Lymphadenitis due to Neisseria cinerea. Lancet. 1984;1:908.CrossRefPubMedGoogle Scholar
  4. 4.
    Bourbeau P, Holla V, Piemonstese S. Ophtalmia neonatorum caused by Neisseria cinerea. J Clin Microbiol. 1990;28:1640–1.PubMedPubMedCentralGoogle Scholar
  5. 5.
    Haqqie SS, Chiu C, Bailie GR. Successful treatment of CAPD peritonitis caused by Neisseria cinerea. Perit Dial Int. 1994;14:193–4.PubMedGoogle Scholar
  6. 6.
    Dossett JH, Appelbaum PC, Knapp JS, Totten PA. Proctitis associated with Neisseria cinerea misidentified as Neisseria gonorrhoeae in a child. J Clin Microbiol. 1985;21:575–7.PubMedPubMedCentralGoogle Scholar
  7. 7.
    Johnson DH, Febre E, Schoch PE, Imbriano L, Cunha BA. Neisseria cinerea bacteremia in a patient receiving hemodialysis. Clin Infect Dis. 1994;19:990–1.CrossRefPubMedGoogle Scholar
  8. 8.
    Southern PM Jr, Kitscher AE. Bacteremia due to Neisseria cinerea: report of two cases. Diagn Microbiol Infect Dis. 1987;7:143–7.CrossRefPubMedGoogle Scholar
  9. 9.
    Kirchgesner V, Plesiat P, Dupont MJ, Estavoyer JM, Guibourdenche M, Riou JY, Michel-Briand Y. Meningitis and septicemia due to Neisseria cinerea. Clin Infect Dis. 1995;21:1351.CrossRefPubMedGoogle Scholar
  10. 10.
    Zhu X, Li M, Cao H, Yang X. Fatal bacteremia by Neisseria cinerea in a woman with myelodysplastic syndrome: a case report. Int J Clin Exp Med. 2015;8:6369–71.PubMedPubMedCentralGoogle Scholar
  11. 11.
    Von Kietzell M, Richter H, Bruderer T, Goldberger D, Emonet S, Strahm C. Meningitis and bacteremia due to Neisseria cinerea following a percutaneous rhizotomy of the trigeminal ganglion. J Clin Microbiol. 2016;54:233–5.CrossRefGoogle Scholar
  12. 12.
    Benes J, Dzupova O, Krizova P, Rozsypal H. Tricuspid valve endocarditis due to Neisseria cinerea. Eur J Clin Microbiol Infect Dis. 2003;22:106–7.PubMedGoogle Scholar
  13. 13.
    Rother RP, Rollins SA, Mojcik CF, Brodsky RA, Bell L. Discovery and development of the complement inhibitor eculizumab for the treatment of paroxysmal nocturnal hemaglobinuria. Nat Biotechnol. 2007;25:1256–64.CrossRefPubMedGoogle Scholar
  14. 14.
    Dmytrijuk A, Robie-Suh K, Cohen MH, Rieves D, Weiss K, Pazdur R. FDA report eculizumab (Soliris) for the treatment of patients with paroxysmal nocturnal hemaglobinuria. Oncologist. 2008;13:993–1000.CrossRefPubMedGoogle Scholar
  15. 15.
    Keating GM. Eculizumab: a review of its use in atypical haemolytic uraemic syndrome. Drugs. 2013;73:2053–66.CrossRefPubMedGoogle Scholar
  16. 16.
    Soliris (package insert). Cheshire, CT: Alexion pharmaceuticals, Inc; 2014.Google Scholar
  17. 17.
    Benamu E, Montoya JG. Infections associated with the use of eculizumab: recommendations for prevention and prophylaxis. Curr Opin Infect Dis. 2016;29:319–29.CrossRefPubMedGoogle Scholar
  18. 18.
    McNamara LA, Topaz N, Wang X, Hariri S, Fox L, MacNeil JR. High risk for invasive meningococcal disease among patients receiving eculizumab (Soliris) despite receipt of meningococcal vaccine. MMWR Morb Mortal Wkly Rep. 2017;66:734–7.CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    Lavender H, Poncin K, Tang CM. Neisseria cinerea expresses a functional factor H binding protein which is recognised by immune responses elicited by meningococcal vaccines. Infect Immun. 2017;85:e00305–17.CrossRefPubMedCentralGoogle Scholar
  20. 20.
    Konar M, Granoff DM. Eculizumab treatment and impaired opsonophagocytic killing of meningococci by whole blood from immunized adults. Blood. 2017;130:891–9.CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany 2017

Authors and Affiliations

  • Thomas L. Walsh
    • 1
    • 2
  • Holly R. Bean
    • 1
    • 2
  • Robert B. Kaplan
    • 3
  1. 1.Division of Infectious DiseaseThe Western Pennsylvania HospitalPittsburghUSA
  2. 2.Division of Infectious DiseaseAllegheny General HospitalPittsburghUSA
  3. 3.Division of Hematology and Cellular TherapyThe Western Pennsylvania HospitalPittsburghUSA

Personalised recommendations